- Home
- Mutual Funds
- HDFC Mutual Fund
- HDFC Pharma And Healthcare Fund Regular-growth
Fund Overview of HDFC Pharma And Healthcare Fund Regular-growth
-
₹2,362.4 CrAUM
-
₹19.56NAV
-
2.24%Expense Ratio
-
EquityFund Category
Minimum amount you can invest: ₹500
Maximum amount you can invest: ₹1,00,000
We have used a return rate of 15% for our calculations.
Returns of HDFC Pharma And Healthcare Fund Regular-growth
| Tenure | Absolute(%) | Annualised(%) | Category Average(%) |
|---|---|---|---|
| 3 Months | 14.48% | NA | 6.12% |
| 6 Months | 14.60% | NA | 12.92% |
| 1 Year | 18.64% | 18.64% | 6.04% |
| 2 Years | 47.66% | 21.52% | 24.93% |
{{compareMutualFunds}}
Asset Allocation
equities
98.68%other assets or cash equivalents
1.32%HDFC Pharma And Healthcare Fund Regular-growth is one Equity mutual fund offered by HDFC Mutual Fund. Launched on 04 Oct 2023, the fund aims To generate long-term capital appreciation Investment predominantly in equity & equity related instruments of Pharma and healthcare companies. It manages assets worth ₹2,362.4 crore as on Sun May 31, 2026. The expense ratio stands at 2.24%. Fund Manager Manager Education Fund Manager Manager EducationAbout HDFC Pharma And Healthcare Fund Regular-growth
The portfolio allocation consists of 98.68% in equities, 1.32% in other assets or cash equivalents.Managed by Nikhil Mathur, it has delivered a return of 18.64% in the last year, a total return since inception of 28.15%.
Based on investment horizon investors often evaluate best sip plan as part of the long-term financial strategy.
Fund Details
|
|
Top Performing Mutual Funds
| Fund Names | AUM (Cr) | 1M | 3M | 1Yr | 3Yr | 5Yr |
|---|---|---|---|---|---|---|
SBI Healthcare Opportunities Fund Direct Plan-growth  |
₹4,566 | 1.67% | 13.30% | 10.49% | 24.74% | 16.80% |
| SBI Healthcare Opportunities Fund Direct Plan-idcw |
₹4,566 | 1.67% | 13.30% | 10.49% | 24.74% | 16.80% |
ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-growth  |
₹6,454 | -1.21% | 11.20% | 7.32% | 26.34% | 16.48% |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-idcw |
₹6,454 | -1.21% | 11.20% | 7.32% | 26.34% | 16.48% |
| Mirae Asset Healthcare Fund Direct-growth |
₹3,091 | -0.79% | 9.54% | 13.22% | 24.88% | 15.73% |
| Mirae Asset Healthcare Fund Direct-idcw |
₹3,091 | -0.79% | 9.54% | 13.22% | 24.88% | 15.73% |
| DSP Healthcare Fund Direct-growth |
₹3,309 | 3.03% | 14.21% | 8.50% | 22.68% | 15.62% |
| DSP Healthcare Fund Direct-idcw |
₹3,309 | 3.03% | 14.21% | 8.50% | 22.68% | 15.62% |
| SBI Healthcare Opportunities Fund-growth |
₹4,566 | 1.58% | 13.02% | 9.38% | 23.45% | 15.57% |
| SBI Healthcare Opportunities Fund-idcw |
₹4,566 | 1.58% | 13.02% | 9.38% | 23.45% | 15.57% |
growth is based on 1-month returns of the funds & Top fund are based on 3Y Returns
More funds from HDFC Mutual Fund
| Fund Names | AUM (Cr) | 1M | 3M | 6M | 1Yr | 3Yr |
|---|---|---|---|---|---|---|
|
HDFC Pharma And Healthcare Fund Direct-growth
|
₹2,362 | 1.77% | 14.80% | 15.25% | 20.02% | - |
|
HDFC Pharma And Healthcare Fund Regular-idcw
|
₹2,362 | 1.67% | 14.48% | 14.60% | 18.64% | - |
|
HDFC Pharma And Healthcare Fund Direct-idcw
|
₹2,362 | 1.77% | 14.80% | 15.25% | 20.02% | - |
growth is based on 1-month returns of the fundsMutual Fund Calculator
- 1
- 2
- 3
- 4
- 6
- 7
- 8
- 9
- 11
- 12
- 13
- 14
- 16
- 17
- 18
- 19
- 21
- 22
- 23
- 24
- 26
- 27
- 28
- 29
- 31
- 32
- 33
- 34
- 36
- 37
- 38
- 39
- 40
- 1
- 2
- 3
- 4
- 6
- 7
- 8
- 9
- 11
- 12
- 13
- 14
- 16
- 17
- 18
- 19
- 21
- 22
- 23
- 24
- 26
- 27
- 28
- 30
- 1
- 2
- 3
- 4
- 6
- 7
- 8
- 9
- 11
- 12
- 13
- 14
- 16
- 17
- 18
- 19
- 21
- 22
- 23
- 24
- 26
- 27
- 28
- 29
- 31
- 32
- 33
- 34
- 36
- 37
- 38
- 39
- 40
- 1
- 2
- 3
- 4
- 6
- 7
- 8
- 9
- 11
- 12
- 13
- 14
- 16
- 17
- 18
- 19
- 21
- 22
- 23
- 24
- 26
- 27
- 28
- 30
Top Mutual Funds
| Fund Names | AUM (Cr) | NAV | 3Yr | 5Yr | 10Yr |
|---|---|---|---|---|---|
| Nippon India Pharma Fund-growth |
₹8,636 | ₹535.25 | 20.43% | 12.64% | 15.21% |
| Nippon India Pharma Fund Direct-growth |
₹8,636 | ₹601.05 | 21.51% | 13.66% | 16.24% |
| Nippon India Pharma Fund-idcw |
₹8,636 | ₹115.58 | 20.43% | 12.64% | 15.21% |
| Nippon India Pharma Fund Direct-idcw |
₹8,636 | ₹164.49 | 21.51% | 13.66% | 16.24% |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund-growth |
₹6,454 | ₹41.36 | 25.28% | 15.47% | - |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-growth |
₹6,454 | ₹44.89 | 26.34% | 16.48% | - |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund-idcw |
₹6,454 | ₹24.13 | 25.28% | 15.47% | - |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-idcw |
₹6,454 | ₹27.11 | 26.34% | 16.48% | - |
| SBI Healthcare Opportunities Fund-growth |
₹4,566 | ₹468.57 | 23.45% | 15.57% | 13.35% |
| SBI Healthcare Opportunities Fund Direct Plan-growth |
₹4,566 | ₹541.52 | 24.74% | 16.80% | 14.59% |
Detailed Portfolio
| Stocks | Sector | % of Holding | Value |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | Healthcare | 9.20% | ₹217.44 Cr |
| Divi's Laboratories Ltd | Healthcare | 8.02% | ₹189.40 Cr |
| Lupin Ltd | Healthcare | 5.45% | ₹128.87 Cr |
| Max Healthcare Institute Ltd | Healthcare | 5.26% | ₹124.37 Cr |
| Aster Dm Healthcare Ltd | Healthcare | 5.18% | ₹122.44 Cr |
| Cipla Ltd | Healthcare | 4.92% | ₹116.29 Cr |
| Ami Organics Ltd | Healthcare | 4.50% | ₹106.19 Cr |
| Alkem Laboratories Ltd | Healthcare | 4.36% | ₹103.08 Cr |
| Anthem Biosciences Ltd. | Healthcare | 4.15% | ₹98.16 Cr |
| Ipca Laboratories Ltd | Healthcare | 3.50% | ₹82.58 Cr |
| Fortis Healthcare Ltd | Healthcare | 3.41% | ₹80.49 Cr |
| Glenmark Pharmaceuticals Ltd | Healthcare | 3.28% | ₹77.55 Cr |
| Laurus Labs Ltd | Healthcare | 3.17% | ₹74.82 Cr |
| Krishna Institute Of Medical Sciences Ltd | Healthcare | 3.16% | ₹74.72 Cr |
| Global Health Ltd | Healthcare | 3.08% | ₹72.76 Cr |
| Neuland Laboratories Ltd | Healthcare | 2.98% | ₹70.43 Cr |
| Vijaya Diagnostic Centre Ltd | Healthcare | 2.70% | ₹63.87 Cr |
| Metropolis Healthcare Ltd | Healthcare | 2.54% | ₹60.06 Cr |
| Zydus Lifesciences Ltd | Healthcare | 2.50% | ₹59.15 Cr |
| Wockhardt Ltd | Healthcare | 2.44% | ₹57.55 Cr |
| Shilpa Medicare Ltd | Healthcare | 2.28% | ₹53.92 Cr |
| Sai Life Sciences Ltd. | Healthcare | 1.78% | ₹41.99 Cr |
| Eris Lifesciences Ltd | Healthcare | 1.61% | ₹37.96 Cr |
| Thyrocare Technologies Ltd | Healthcare | 1.54% | ₹36.41 Cr |
| Repo | Unspecified | 1.49% | ₹35.12 Cr |
| Rubicon Research Ltd. | 1.35% | ₹31.90 Cr | |
| Jubilant Pharmova Ltd | Healthcare | 1.34% | ₹31.60 Cr |
| Biocon Ltd | Healthcare | 1.33% | ₹31.43 Cr |
| Gland Pharma Ltd | Healthcare | 1.19% | ₹28.17 Cr |
| Bajaj Healthcare Ltd | Healthcare | 0.73% | ₹17.19 Cr |
| Novartis India Ltd | Healthcare | 0.64% | ₹15.10 Cr |
| Laxmi Dental Ltd. | Healthcare | 0.63% | ₹14.99 Cr |
| Suven Pharmaceuticals Ltd | Healthcare | 0.46% | ₹10.79 Cr |
| Net Payables | Unspecified | -0.17% | ₹-4.35 Cr |
Top Equity Funds
| Fund Names | NAV | 3Yr | 5Yr | 52 weeks high |
|---|---|---|---|---|
| SBI Healthcare Opportunities Fund Direct Plan-growth |
₹541.52 | 24.74% | 16.80% | - |
| SBI Healthcare Opportunities Fund Direct Plan-idcw |
₹376.23 | 24.74% | 16.80% | - |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-growth |
₹44.89 | 26.34% | 16.48% | - |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-idcw |
₹27.11 | 26.34% | 16.48% | - |
| Mirae Asset Healthcare Fund Direct-growth |
₹47.24 | 24.88% | 15.73% | - |
| Mirae Asset Healthcare Fund Direct-idcw |
₹28.45 | 24.88% | 15.73% | - |
| DSP Healthcare Fund Direct-growth |
₹46.19 | 22.68% | 15.62% | - |
| DSP Healthcare Fund Direct-idcw |
₹26.71 | 22.68% | 15.62% | - |
| SBI Healthcare Opportunities Fund-growth |
₹468.57 | 23.45% | 15.57% | - |
| SBI Healthcare Opportunities Fund-idcw |
₹295.17 | 23.45% | 15.57% | - |
growth is based on 5Y returns of the funds
Frequently Asked Questions
HDFC Pharma And Healthcare Fund Regular-growth
What is the current AUM of HDFC Pharma And Healthcare Fund Regular-growth?
As of Sun May 31, 2026, HDFC Pharma And Healthcare Fund Regular-growth manages assets worth ₹2,362.4 crore
How has HDFC Pharma And Healthcare Fund Regular-growth performed recently?
- 3 Months: 14.48%
- 6 Months: 14.60%
What is the long-term performance of HDFC Pharma And Healthcare Fund Regular-growth?
- Since Inception: 28.15%
What is the portfolio composition of HDFC Pharma And Healthcare Fund Regular-growth?
Equity: 98.68%, Others: 1.32%.
Who manages HDFC Pharma And Healthcare Fund Regular-growth?
HDFC Pharma And Healthcare Fund Regular-growth is managed by Nikhil Mathur from HDFC Mutual Fund.
What is the market-cap allocation of HDFC Pharma And Healthcare Fund Regular-growth?
Large Cap: 27.77%, Mid Cap: 34.69%, Small Cap: 37.55%.
Which are the top companies HDFC Pharma And Healthcare Fund Regular-growth has invested in?
- Sun Pharmaceutical Industries Ltd – 9.20% of the fund's portfolio
- Divi's Laboratories Ltd – 8.02% of the fund's portfolio
- Lupin Ltd – 5.45% of the fund's portfolio
- Max Healthcare Institute Ltd – 5.26% of the fund's portfolio
- Aster DM Healthcare Ltd – 5.18% of the fund's portfolio
Which are the major sectors HDFC Pharma And Healthcare Fund Regular-growth focuses on?
- Healthcare – 97.33% of the fund's portfolio
- Other – 1.35% of the fund's portfolio
- Unspecified – 1.32% of the fund's portfolio
Policybazaar does not endorse rates/returns or recommend any particular insurer, fund house, AMC (Asset Management Company), insurance and mutual fund product.
Please consult your financial advisor for an informed decision.
Past performance may not be indicative of future results.
The information presented on this page is not owned or generated by Policybazaar. The data has been collected from publicly available sources and online research. We do not claim any ownership or guarantee the accuracy, completeness, or timeliness of this information. It is shared solely for the informational purpose of the viewer and should not be considered as financial advice.
Policybazaar is not acting as a financial advisor, broker, or agent for any mutual fund mentioned here.
Mutual fund investments are subject to market risks. Please read all scheme-related documents carefully before investing.
Policybazaar shall not be held responsible or liable for any losses, damages, or decisions made based on the information provided on this page.
For a complete list of mutual funds registered in India, please refer to the Securities and Exchange Board of India (SEBI) website at www.sebi.gov.in. We do not sell, endorse, or recommend any mutual fund or investment product. For a complete list of mutual funds registered in India, please refer to the Securities and Exchange Board of India (SEBI) website at www.sebi.gov.in. We do not sell, endorse, or recommend any mutual fund or investment product.
For more details on risk factors, terms, and conditions, please read the sales brochure and benefit illustration carefully before concluding a sale.
Policybazaar is a registered Insurance Broker | Registration No. 742, Registration Code No. IRDA/ DB 797/ 19, Valid till 09/06/2024, License category- Direct Broker (Life & General) |CIN: U74999HR2014PTC053454 | Registered Office - Plot No.119, Sector - 44, Gurgaon, Haryana – 122001 |Visitors are hereby informed that their information submitted on the website may be shared with insurers. Product information is authentic and solely based on the information received from the insurers.©️ Copyright 2008-2025 policybazaar.com. All Rights Reserved
^Returns as on 10th Jan’25. Tata AIA Life Top 200 ULIP Fund has delivered 18% returns over the last 10 years. Past performance is not necessarily indicative of future results. This disclaimer is specifically regarding a ULIP fund and is not related to mutual funds. Source: Morningstar.
